CENTOGENE

The Rare Disease Company CENTOGENE - transforming genetic data into medical decisions.

We are one of the worldwide leaders in the field of early genetic diagnostics for rare hereditary diseases. A data repository of genetic data from over 115 countries gives us a unique access to epidemiological, clinical and genetic information on hereditary disorders, including oncogenetic indications. We focus exclusively on providing the highest quality, patient-centred service, verified by multiple international accreditations (ISO, CAP, CLIA), regular pharmaceutical audits and our outstanding short turn-around times for analysis. We believe our medical expertise is based on cutting-edge technologies including whole exome/genome sequencing, innovative biomarkers and continued R&D. Our mutation database (CentoMD®) is the world’s largest for rare genetic diseases and is pivotal to our high-quality diagnostic reporting and comprehensive medical interpretation. CENTOGENE is a key partner for many high-profile pharmaceutical companies who are active in the orphan drug development.

22/12/2025

✨ 𝗛𝗮𝗽𝗽𝘆 𝗛𝗼𝗹𝗶𝗱𝗮𝘆𝘀 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗖𝗘𝗡𝗧𝗢𝗚𝗘𝗡𝗘 𝗳𝗮𝗺𝗶𝗹𝘆
As the year comes to an end, we would like to thank our partners and colleagues for their trust and commitment.
We wish you a joyful holiday season and a healthy and successful year ahead. We look forward to continuing to Guide Precision Medicine together 🌍🧬

15/12/2025

CentoCustom Panel - 𝗨𝗽𝗱𝗮𝘁𝗲𝗱
As genetic knowledge evolves, providing clinicians with the flexibility to build highly targeted and comprehensive diagnostic panels is more important than ever. To support this, our offering includes 4,370 genes available for panel customization, within a total gene universe of 25,000.

29/10/2025

The Precision Medicine Tool is now updated! Our customizable genetic testing solution, 𝗖𝗲𝗻𝘁𝗼𝗖𝘂𝘀𝘁𝗼𝗺 𝗣𝗮𝗻𝗲𝗹: NOW with additional options available for including research genes.

With improved flexibility we are empowering you to design a custom gene panel tailored to each individual case with CENTOGENE’s quality and expertise in medical interpretation.

Want to Learn More?

Save the Date: November 13th. CentoCustom Panel Webinar

22/10/2025

A groundbreaking publication in Nature Communications, led by researchers from our R&D partner Fundación Carlos Simón and its biotechnology spin-off iPremom.

The study demonstrates that maternal plasma cell-free RNA (cfRNA) can accurately predict both early- and late-onset preeclampsia weeks before clinical symptoms appear — paving the way for non-invasive, subtype-specific prenatal screening.

These findings open the door to earlier and more precise detection of preeclampsia — a major step toward improving outcomes for mothers and babies worldwide — and support the clinical implementation of iPremom’s MaiRa Test for early risk stratification.

We are truly proud and grateful to collaborate with such visionary teams driving innovation in women’s health and reproductive medicine — and we look forward to continuing this journey together.

Read the full article in Nature Communications

13/10/2025

Get ready to decode Gaucher Disease! Join us for our upcoming on October 16th and explore these exciting topics with our expert speakers:

1. The Disease Background
2. Diagnosing Gaucher: The Multiomic Approach (Patient Cases)
3. Pharma Services: How We Support Clinical Trials
4. Real-World Impact: LysoProof Study

🎙️ Speakers:
Peter Bauer - Chief Medical and Genomic Officer
Eleni Perrakis, PhD - Senior Product Manager

Can’t attend the live session?
👉 Register now, and you’ll receive access to the webinar recording to watch at your convenience.

01/10/2025

🌍 𝗧𝗼𝗱𝗮𝘆, 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟏𝘀𝘁, 𝗺𝗮𝗿𝗸𝘀 𝘁𝗵𝗲 𝘀𝘁𝗮𝗿𝘁 𝗼𝗳 𝗚𝗮𝘂𝗰𝗵𝗲𝗿 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗠𝗼𝗻𝘁𝗵

A time when patients, families, advocates, and healthcare professionals come together to raise awareness and support for those living with Gaucher disease.

We are excited to host a special webinar: Decoding Gaucher

📅 Thursday, October 16th | 🕓 4:00 PM CEST

Join us to learn more about the Gaucher patient journey and gain insights from experts in the field.

05/09/2025

❤️ September is all about cardiovascular health awareness – and we’re celebrating with the launch of our new Cardiology Portfolio

Why does it matter?
✅ Early detection can change lives
✅ Lower risk of sudden cardiac death
✅ Better patient outcomes

What’s new?
CentoCardioVascular Panel – now powered by CentoGenome
22 new panels designed for hereditary heart disorders

💡 Discover the full portfolio in centogene.com

12/08/2025

August is SMA Awareness Month 🧠💙 Spinal Muscular Atrophy is a progressive neurodegenerative disease that causes muscle weakness and atrophy — and up to 70% of patients with neurological diseases remain genetically undiagnosed.

At CENTOGENE, we’re committed to Guiding Precision Medicine with advanced diagnostics, including our Neuromuscular Disorders Panel Upgraded Genome — now with enhanced SMN1 detection for accurate SMA diagnosis.

🔬 Early, precise diagnosis changes lives.

30/06/2025

Our red duck never misses a trip 🦆✈️

They say ducks only walk forward…just like us: always moving forward.

Come meet us (and the duck!) at Booth

26/06/2025

The countdown has begun! In just a few days, Paris will host the brightest minds in reproductive medicine at the 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗦𝗼𝗰𝗶𝗲𝘁𝘆 𝗼𝗳 𝗛𝘂𝗺𝗮𝗻 𝗥𝗲𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗘𝗺𝗯𝗿𝘆𝗼𝗹𝗼𝗴𝘆 (𝗘𝗦𝗛𝗥𝗘) — and CENTOGENE will be right at the center of it all.

✨ Get a sneak peek before the doors open:
Explore what we’re bringing to ESHRE 2025 and how we’re driving the future of reproductive health with our advanced multiomic technologies.

🔗 Find our event page on our Bio

📍 Booth |🗓️ 29 June – 2 July | Paris, France

Let’s shape the future of reproductive medicine together.

20/06/2025

New CentoScreen Genome
Plan your future with precision medicine.

Our most comprehensive carrier screening test helps assess the risk of over 2,000 recessive genetic disorders — all in one test.

✔️ Powered by Whole Genome Sequencing
✔️ High accuracy
✔️ Advanced variant detection
✔️ Ideal for family planning

To learn more visit our Website.

21/05/2025

A new chapter for CENTOGENE

With a new claim, a redefined focus and the backing of Charme Capital Partners, we are ready to expand into new clinical areas and markets.

Adresse

Am Strande 7
Rostock
18055

Telefon

+4938180113416

Webseite

http://www.centogene.com/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von CENTOGENE erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.